It is therefore not surprising that combinatorial therapies utilizing an AKT inhibitor such as MK-2206 and the MEK inhibitor, AZD-6244, in patients with relapsed BRAFV600E positive melanomas (clinical trial NCT01510444) are in clinical testing. This evidence concerns the gene MAP2K7 and melanoma.